1 / 22

Early Detection and Prevention of Renal Failure

Early Detection and Prevention of Renal Failure. Linda Fried, MD, MPH. Scope of the Problem. The incidence of End-stage renal disease is growing As of 12/31/98, there were more than 200,000 people in the US on dialysis* End-stage renal disease care accounted for >16 billion dollars in 1998*

pearl-jensen
Télécharger la présentation

Early Detection and Prevention of Renal Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH

  2. Scope of the Problem • The incidence of End-stage renal disease is growing • As of 12/31/98, there were more than 200,000 people in the US on dialysis* • End-stage renal disease care accounted for >16 billion dollars in 1998* • The major causes of ESRD are diabetes (45%) and hypertension (24%) and are therefore potentially preventable • ESRD disproportionately affects minorities and the elderly *USRDS

  3. Incident rates of ESRD Due to Diabetes & Hypertension, by RaceRateper million population, adjusted for age & gender USRDS

  4. Incident Rates, by Age & First Modalityadjusted for gender & race USRDS

  5. Incident Rates, by Primary Diagnosis & First Modalityadjusted for age, gender, & race USRDS

  6. Identifying People with Early Renal Disease • Proteinuria • Microalbuminuria • Overt Proteinuria/Albuminuria- associated with lower Creatinine clearance in population* • Serum Creatinine- miss early declines in GFR • Creatinine Clearance- difficult to do as screen • Estimated glomerular filtration rate (GFR) - formulas from laboratory/clinical variables *Pinto-Sietsma et al, Groningen, Netherlands, JASN 2000

  7. Proposed NKF Clinical Practice Guideline for Stages of Kidney Disease

  8. Proposed NKF Clinical Practice Guideline for Stages of Kidney Disease *Proteinuria, Urinary sediment abnormalities, Structural abnormalities, Alterations in composition of the urine

  9. Proteinuria • The level of proteinuria is a prognostic factor in renal disease • This is true for a wide variety of diseases, including hypertensive renal diseases • Easily performed • Urine dipstick • Albumin sticks • Protein or albumin/creatinine ratio on spot urine

  10. Should we be screening for proteinuria or an elevated creatinine? • All diabetics should be screened for microalbuminuria - ADA and NKF recommendation • In the US, the prevalence of proteinuria is low in subjects without hypertension or diabetes • US Preventive Health Services Task Force does not recommend urinalysis or creatinine as screen in otherwise healthy adults • Are there higher risk groups, such as African Americans or older individuals where screening should be done in asymptomatic individuals without diabetes or hypertension?

  11. Prevalence of Albuminuria in Individuals Without Diabetes: NHANES III

  12. Prevalence of an Increased Creatinine* in Normal, High Normal, and Stage 1 Hypertension : NHANES III *Cr  1.6 men, 1.4 women, Coresh et al, Arch Intern Med 2001

  13. Screening for Renal Disease • Many of those with early renal disease have not been informed of the diagnosis • In a small pilot study, only 36% (9 of 25) of patients with a creatinine between 1.5 and 3.0 knew of their renal disease

  14. Screening for Renal Disease • Microalbuminuria • Risk factor for cardiovascular events and in nondiabetics this may be a reason to screen, especially in the elderly • It is a risk factor for progression of diabetic nephropathy, unknown if it is a risk factor in nondiabetics • Overt proteinuria also identifies those at risk for subsequent events* • An elevated creatinine identifies not only those at risk for progression of renal disease, but also those at higher risk for mortality and cardiovascular events *NHANES 1, Wagener et al Environ Res 1994

  15. Cardiovascular Health Study • Population-based, longitudinal study of 5,888 individuals, age >65 years • Random sample from Medicare eligibility lists in: • Pittsburgh, PA • Forsyth County, NC • Washington County, MD • Sacramento County, CA • Primary objective of CHS is to identify risk factors related to coronary heart disease and stroke

  16. Baseline Cardiovascular Risk in Subjects with an Elevated Creatinine ( 1.5 men or 1.3 women) N=578 Elderly with Renal Insufficiency N=208 N=370 Clinical CV Disease NO 64% YES 36% N=161 N=209 Subclinical CV Disease YES 28% NO 36% N=14 N=195 Diabetes Mellitus YES 2% NO 34% N=32 N=163 Framingham Risk > 20% / 10 years YES 6% NO 28%

  17. Survival of Elderly Subjects in CHS by Baseline Creatinine Level

  18. Relative Risk for Cardiovascular Disease: Unadjusted and Fully Adjusted Models

  19. Preventing Decline in Renal Function • Hypertension Control • Angiotensin Converting Enzyme Inhibitors/ Angiotensin Receptor Blockers • Control of Diabetes • Lipid Reduction • Smoking cessation- smoking is associated with a faster decline, no intervention studies • Low Protein Diet- falling out of favor

  20. Multifactorial Intervention Slows Progression to Nephropathy in Diabetes: Steno Study • 160 Type 2 Diabetes, stratified by level of proteinuria (30-100mg/day, 101-300 mg/day) • Randomized to standard or intensive management • Intensive Therapy: behavioral modification (diet, exercise, smoking cessation) and pharmacologic therapy in step-wise fashion • Primary endpoint was nephropathy (albumin excretion rate >300mg/24 hours) Lancet 1999

  21. Steno Study Treatment Goals

  22. Steno Results • 8 patients (11%) in intensive vs 19 (25%) in standard therapy grouped developed overt nephropathy after 4 years (p=0.01) • No patient developed end-stage renal disease • Lower risk of progression, but not development of retinopathy • Lower risk of progression of autonomic neuropathy • No difference in CVD events, though numbers were small • Trend towards fewer patients developing a drop in AAI

More Related